NCT06369935View on ClinicalTrials.gov

A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.

Not yet recruitingOBSERVATIONAL

Enrollment

260

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

August 20, 2026

Study Completion Date

August 20, 2027

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

DRUG

Equecabtagene Autoleucel

Equecabtagene Autoleucel (CT103A) is a novel fully human BCMA-targeting CAR-T therapy

Trial Locations (1)

Unknown

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Peking University People's Hospital

OTHER

NCT06369935 - A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma. | Biotech Hunter | Biotech Hunter